By Mirko Hirschmann
Obesity and type II diabetes are no longer only clinical challenges; they are also workforce, productivity, and health-equity challenges. Globally, WHO reports that 2.5 billion adults were overweight in 2022, including more than 890 million people living with obesity, while about 830 million people worldwide live with diabetes. In England alone, 64.5% of adults were estimated to be overweight or living with obesity in 2023/24, and diabetes cost the UK almost £14 billion in 2021/22.
At Tau20, we were excited to connect with THIER, a London-based AI-enabled mobile platform for the prevention of lifestyle diseases such as obesity and type II diabetes. THIER aims to help employers, heads of wellbeing, and occupational-health teams identify, measure, track, and predict lifestyle-disease risk in employee populations before a visit to the doctor is required.
The company’s materials position the solution around four components: DataHubPro for enterprise health data, Prevencio AI for predictive metabolic-risk profiling, HealthIQ for personalised tracking and coaching, and Navigate for health-practitioner support.
The key question quickly became: how can THIER’s prevention logic be translated into impact evidence that investors, employers, and healthcare stakeholders can understand?
“Participating in the Tau20 program was a watershed moment for the THIER team. The platform provided the essential frameworks needed to identify our primary SDG targets , define trackable IRIS+ metrics , and project our long-term socio-economic impact. Most importantly, it enabled us to design a rigorous milestone roadmap that clearly demonstrates to future impact investors how we will systematically embed these global goals as our company matures. We cannot recommend this program highly enough to fellow mission-driven founders.”
– Kofo Mary Are, THIER
Tau20 Impact Readiness Sprint Participant
First, Tau20’s AI researched and pre-structured information on THIER and its solution. We then iterated with expert input and company information to map THIER’s primary impact to SDG 3.4: reducing premature mortality from non-communicable diseases, with secondary links to SDG 8: Decent Work and Economic Growth, SDG 10: Reduced Inequalities, and SDG 17: Partnerships for Data.
The impact logic is straightforward: better enterprise health-data integration and AI-enabled risk stratification should enable earlier identification of employees at elevated metabolic risk; personalised behavioural coaching should support sustained habit change; and improved risk profiles should reduce type II diabetes incidence, absenteeism, productivity losses, and preventable healthcare spending.
In THIER’s theory of change, this translates into a prevention pathway: employee screening -> personalised risk profiles -> behaviour-change coaching and practitioner navigation -> high-to-low risk migration -> avoided type II diabetes cases and cost savings. The assumptions are explicit: large employers adopt the platform, wearable and health data are accessible, engagement persists beyond the initial 100-day period, and the Diabetes Prevention Program benchmark of around 58% relative risk reduction is a relevant long-term reference point.
Tau20 uses the established IRIS+ framework and adds AI-supported metric matching so that startups can move from broad impact claims to metrics they can actually collect. For THIER, the core metrics can be embedded directly into the product and employer reporting workflow:
– Individuals screened annually: THIER’s deck sets a year-one target of 10,000 employee screenings, aligned with the idea of tracking patients or individuals screened.
– Condition addressed: Obesity and type II diabetes, with a focus on prevention and early risk detection.
Population risk stratification shift: Movement from high to lower risk categories, measured at 6, 12, 18, and 24 months.
– Historically marginalized clients reached: THIER’s deck proposes tracking representation, with a 15% annual user-base target.
– Healthcare and productivity-cost savings: Reduction in employer or employee health-related spend, with THIER’s materials suggesting a 10-20% reduction target in annual spend per employee.
At global level, THIER’s addressable problem is large: the company’s deck refers to a global baseline of 537 million adults living with diabetes, while WHO’s current global estimate is around 830 million people with diabetes. Rather than translating the whole global disease burden into an unrealistic headline number, a more credible impact estimate should be expressed per adoption volume: for every 1 million employees screened annually, a realistic scenario suggests roughly 1,000-16,000 type II diabetes cases avoided per year, assuming that 25-40% of screened employees are high-risk or prediabetic, 5-10% would otherwise progress annually, 50-70% remain sufficiently engaged, and THIER realizes 30-58% relative risk reduction compared with no structured prevention support.
For the UK, where THIER is initially positioned, a realistic national at-scale scenario would be around 250,000-500,000 employees screened annually through large employers and occupational-health channels. Under the same assumptions, this implies approximately 300-8,000 type II diabetes cases avoided annually, with additional but separately measurable benefits from reduced absenteeism, healthcare claims, and productivity losses; the monetary impact should only be reported once employer pilots establish credible baseline cost per employee and observed changes over time.
Finally, Tau20 can issue an Impact Readiness Index result for THIER, packaged with a draft metrics plan and evidence roadmap. For a pre-seed or seed-stage digital-health company, this is especially useful because the impact case depends not only on the technology, but also on employer adoption, employee engagement, data quality, and outcome validation over time.
For THIER, the next evidence step is clear: validate the platform with beta customers, establish pre/post risk-stratification data, measure sustained engagement after 100 days, and quantify whether high-risk employees actually migrate into lower-risk categories over 6-24 months. This would turn THIER’s prevention claim into a measurable employer-health and impact-investor case.